$1.44
2.13% yesterday
Nasdaq, Sep 03, 10:00 pm CET
ISIN
US05280R1005
Symbol
AUTL

Autolus Therapeutics plc Stock price

$1.44
-0.94 39.50% 1M
-0.31 17.71% 6M
-0.91 38.72% YTD
-2.41 62.60% 1Y
-1.74 54.72% 3Y
-11.41 88.79% 5Y
-23.56 94.24% 10Y
-23.56 94.24% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
+0.03 2.13%
ISIN
US05280R1005
Symbol
AUTL
Industry

Key metrics

Basic
Market capitalization
$375.3m
Enterprise Value
$165.6m
Net debt
positive
Cash
$454.3m
Shares outstanding
266.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
12.5 | 5.1
EV/Sales
5.5 | 2.2
EV/FCF
negative
P/B
1.1
Financial Health
Equity Ratio
54.6%
Return on Equity
-51.6%
ROCE
-41.4%
ROIC
-108.6%
Debt/Equity
0.7
Financials (TTM | estimate)
Revenue
$29.9m | $74.3m
EBITDA
$-261.3m | $-231.6m
EBIT
$-270.0m | $-248.0m
Net Income
$-227.8m | $-233.5m
Free Cash Flow
$-312.0m
Growth (TTM | estimate)
Revenue
- | 634.3%
EBITDA
- | 0.6%
EBIT
- | -3.0%
Net Income
- | -5.8%
Free Cash Flow
-93.8%
Margin (TTM | estimate)
Gross
-79.7%
EBITDA
-873.0% | -311.6%
EBIT
-901.9%
Net
-760.9% | -314.2%
Free Cash Flow
-1,042.2%
More
EPS
$-0.9
FCF per Share
$-1.2
Short interest
7.4%
Employees
649
Rev per Employee
$20.0k
Show more

Is Autolus Therapeutics plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Autolus Therapeutics plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Autolus Therapeutics plc forecast:

16x Buy
94%
1x Hold
6%

Analyst Opinions

17 Analysts have issued a Autolus Therapeutics plc forecast:

Buy
94%
Hold
6%

Financial data from Autolus Therapeutics plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
30 30
-
100%
- Direct Costs 54 54
-
180%
-24 -24
-
-80%
- Selling and Administrative Expenses 121 121
-
404%
- Research and Development Expense 125 125
-
419%
-261 -261
-
-873%
- Depreciation and Amortization 8.66 8.66
26% 26%
29%
EBIT (Operating Income) EBIT -270 -270
-
-902%
Net Profit -228 -228
-
-761%

In millions USD.

Don't miss a Thing! We will send you all news about Autolus Therapeutics plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Autolus Therapeutics plc Stock News

Positive
Seeking Alpha
23 days ago
I remain bullish on Autolus Therapeutics as they advance their CAR T-cell therapy, obe-cel, in a competitive leukemia market. Obe-cel shows durable benefits, with 38% of responders at 33 months needing no further therapy, suggesting potential as a definitive treatment. Recent EU approval and expansion into new indications like non-Hodgkin lymphoma and autoimmune diseases strengthen AUTL's marke...
Neutral
Seeking Alpha
23 days ago
Autolus Therapeutics plc (NASDAQ:AUTL ) Q2 2025 Earnings Conference Call August 12, 2025 8:30 AM ET Company Participants Amanda Cray - Corporate Participant Christian Martin Itin - CEO & Director Robert F. Dolski - Senior VP, CFO & Principal Accounting Officer Conference Call Participants Asthika Sarith Goonewardene - Truist Securities, Inc., Research Division Dingding Shi - Jefferies LLC, Rese...
Neutral
GlobeNewsWire
23 days ago
Company reports Q2 2025 AUCATZYL® net product revenue of $20.9 million and $29.9 for the first six months of 2025 Company recently received conditional marketing authorization from U.K. Medicines and Healthcare products Regulatory Agency (MHRA) and conditional European marketing authorization from the European Commission (EC) for AUCATZYL® Follow up data from the FELIX trial demonstrating obe-c...
More Autolus Therapeutics plc News

Company Profile

Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Christian Itin
Employees 649
Founded 2014
Website www.autolus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today